PRODUCT INFORMATION

Vorasidenib

Item No. 28462

CAS Registry No.:	1644545-52-7
Formal Name:	6-(6-chloro-2-pyridinyl)-N^2,N^4-*bis*[(1R)-2,2,2-trifluoro-1-methylethyl]-1,3,5-triazine-2,4-diamine
Synonym:	AG-881
MF:	$C_{14}H_{13}ClF_6N_6$
FW:	414.7
Purity:	≥98%
UV/Vis.:	λ_{max}: 218, 284 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vorasidenib is supplied as a crystalline solid. A stock solution may be made by dissolving the vorasidenib in the solvent of choice, which should be purged with an inert gas. Vorasidenib is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of vorasidenib in these solvents is approximately 30 mg/ml.

Vorasidenib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, vorasidenib should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Vorasidenib has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Vorsidenib is an inhibitor of mutant isocitrate dehydrogenase (IDH; IC_{50}s = 31.9 and 31.7 nM for $IDH1^{R132H}$ and $IDH2^{R140Q}$, respectively).[1] It also inhibits wild-type-$IDH1^{R132H}$ and wild-type-$IDH2^{R140Q}$ heterodimers (IC_{50}s = 4 and 251 nM, respectively).[2] Vorsidenib decreases the production of D-2-hydroxyglutarate (2-HG; Item Nos. 25895 | 11605) in TF-1 leukemia cells expressing $IDH1^{R132H}$ or $IDH2^{R140Q}$ (IC_{50}s = 3.2 and 14 nM, respectively). It reduces tumor growth in a TS603-$IDH1^{R132H}$ mouse xenograft model when administered at a dose of 50 mg/kg.[3]

References

1. Ma, R. and Yun, C.-H. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2. *Biochem. Biophys. Res. Commun.* **503(4),** 2912-2917 (2018).
2. Yen, K., Konteatis, Z., Sui, Z., *et al.* AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies. *AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics* **17(Suppl. 1),** (2017).
3. Nicolay, B., Narayanaswamy, R., Amatangelo, M.D., *et al.* Exth-34. Combined use of pan-IDH mutant inhibitor AG-881 with radiation therapy shows added benefit in an orthotopic IDH1 mutant glioma model *in vivo*. *Neuro. Oncol.* **19(Suppl. 6),** vi79 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM